Clinical associations of C-reactive protein in systemic sclerosis

Terapevticheskii Arkhiv

Volumn 78, Issue 6, 2006, Pages 30-35

  Alekperov, R T ^a   Baranov, A A ^a   Abaitova, N E ^a  

^a NONE

Author keywords

C reactive protein; Clinical manifestations; Systemic sclerosis; Von Willebrand factor antigen

Indexed keywords

ANTIGEN; C REACTIVE PROTEIN; VON WILLEBRAND ANTIGEN;

ADULT; AGED; ARTICLE; FEMALE; HUMAN; IMMUNOLOGY; ISCHEMIA; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; SKIN; SYSTEMIC SCLEROSIS; VASCULAR ENDOTHELIUM; VASCULARIZATION;

ADULT; AGED; ANTIGENS; C-REACTIVE PROTEIN; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; ISCHEMIA; MALE; MIDDLE AGED; SCLERODERMA, SYSTEMIC; SKIN;

EID: 33746791907     PISSN: 00403660     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Campbell P. M., LeRoy E. C. Pathogenesis of systemic sclerosis: A vascular hypothesis. Semin. Arthr. Rheum. 1975; 4: 351-368.
2. Krieg T., Meurer M. Systemic scleroderma: clinical and pathophysiologic aspects. J. Am. Acad. Dermatol. 1988; 18: 457-481.
3. LeRoy E. C., Trojanowska M., Smith E. A. The pathogenesis of scleroderma (systemic sclerosis, SSc). Clin. Exp. Rheumatol. 1991; 9: 173-177.
4. Prescott R. J., Freemont A. J., Jones C. J. et al. Sequential dermal microvascular and perivascular changes in the development of scleroderma. J. Pathol. 1992; 166: 255-263.
5. Fleischmajer R., Perlish J. S., Reeves J. R. T. Cellular infiltrates in scleroderma skin. Arthr. and Rheum. 1977; 20 (4): 975-984.
6. Kraling B. M., Maul G. G., Jimenez S. A. Mononuclear cellular infiltrates in clinically involved skin from patients with systemic sclerosis of recent onset predominantly consist of monocytes/macrophages. Pathobiology 1995; 63 (1): 48-56.
7. Kahaleh M. B., LeRoy E. C. Autoimmunity and vascular involvement in systemic sclerosis (SSc). Autoimmunity 1999; 31 (3): 195-214.
8. Moyssakis I., Gialafos E., Vassiliou V. et al. Aortic stiffness in systemic sclerosis is increased independently of the extent of skin involvement. Rheumatology 2005; 44 (2): 251-254.
9. Ho M., Veale D., Eastmond C. et al. Macrovascular disease and systemic sclerosis. Ann. Rheum. Dis. 2000; 59: 39-43.
10. Veale D. J., Collidge T. A., Belch J. J. F. Increased prevalence of symptomatic macrovascular disease in systemic sclerosis. Ann. Rheum. Dis. 1995; 54: 853-855.
11. Olsson A., Elling P., Elling H. Serological and immunochemical determination of von Willebrand factor antigen in serum and biopsy specimens from patients with arterities temporalis and polymyalgia rheumatica. Clin. Exp. Rheumatol. 1990; 8: 55-58.
12. Zwede M., Kitas G. D., Lugmani R., Bacon P. A. Kinetics of von Willebrand (vWF) and angiotensin converting enzyme (ACE) release by endothelial cells (EC) in vitro. Br. J. Rheumatol. 1995; 34 (suppl. 1): 23.
13. Tep. apx. 1993; 5: 15-19.
14. Woolf A. D., Wakerley G., Wellington T. B. et al. Factor VIII related antigen in the assessment of vasculitis. Ann. Rheum. Dis. 1987; 46 (6): 441-447.
15. Sakai H., Coto S., Kim I. Y. et al. Plasma concentration of von Willebrand factor in acute myocardial infarction. Thromb. Haemost. 2000; 84 (2): 204-209.
16. Ray K. K., Morrow D. A., Gibson C. M. et al. Predictors of the rise in vWF after ST elevation myocardial infarction: implications for treatment strategies and clinical outcome: An ENTIR-TIMI 23 substudy. Eur. Heart J. 2005; 26 (5): 241-422.
17. Ibrahim H. A., El-Meligi A. A., Abdel-Hamid M., Elhendy A. Relations between von Willebrand factor, markers of oxidative stress and microalbuminuria in patients with type 2 diabetes mellitus. Med. Sci. Monit. 2004; 10 (3): CR85-CR89.
18. Lopes A. A., Maeda N. Y. Circulating von Willebrand factor antigens as a predictor of short-term prognosis in pulmonary hypertension. Chest 1998; 114 (5): 1276-1282.
19. Collados M. T., Sandoval J., Lopez S. et al. Heart Vessels 1999; 14 (5): 246-252.
20. Kahaleh M. B., Osborn I., LeRoy E. C. Increased factor VIII/von Willebrand factor antigen and von Willebrand factor activity in scleroderma and in Raynaud's phenomenon. Ann. Intern. Med. 1981; 94 (4, pt 1): 482-484.
21. Blann A. D., Sheeran T. P., Emery P. von Willebrand factor: increased levels are related to poor prognosis in systemic sclerosis and not to tissue autoantibodies. Br. J. Biomed. Sci. 1997; 54 (1): 5-9.
22. Greaves M., Malia R. G., Milford Ward A. et al. Elevated von Willebrand factor antigen in systemic sclerosis: relationship to visceral disease. Br. J. Rheumatol. 1988; 27 (4): 281-285.
23. Cerinic M. M., Valentini G., Sorano G. G. et al. Blood coagulation, fibrinolysis, and markers of endothelial dysfunction in systemic sclerosis. Semin. Arthr. Rheum. 2003; 32 (5): 285-295.
24. Matucci-Cerinic M., Pignone A., Lotti T. et al. Reduced angiotensin converting enzyme plasma activity in scleroderma. A marker of endothelial injury? J. Rheumatol. 1990; 17 (3): 328-330.
25. Belch J. J., Zoma A. A., Richards I. M. et al. Vascular damage and factor-VIII-related antigen in the rheumatic diseases. Rheumatol. Int. 1987; 7 (3): 107-111.
26. Lugmani R. A., Bacon P. A., Moors R. J. et al. Birmingham vasculitis activity score (BVAS) in systemic necrotising vasculitis. Quart. J. Med. 1994; 87: 671-678.
27. Maksimowicz-McKinnon K., Bhatt D. L., Calabrese L. H. Recent advances in vascular inflammation: C-reactive protein and other inflammatory biomarkers. Curr. Opin. Rheum. 2004; 16: 18-24.
28. Heinrich J., Schulte H., Schonfeld R. et al. Association of variables of coagulation, fibrinolisis and acute-phase with atherosclerosis of coronary and peripheral arteries and those arteries supplying the brain. Thromb. Haemost. 1995; 73 (3): 374-378.
29. Liuzzo G., Biasucci L., Gallimore J. et al. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N. Engl. J. Med. 1994; 331 (7): 417-424.
30. Ridker P. M., Cushman M., Stampfer M. J. et al. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation 1998; 97: 425-428.
31. Ballou C. P., Lozanski G. Induction of inflammatory cytokine release from cultured human monocytes by C-reactive protein. Cytokine 1992; 4: 361-368.
32. Pasceri V., Willerson J. T., Yeh E. T. H. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000; 102: 2165-2168.
33. Devaraj S., Xu D., Jialal I. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells. Implication for the metabolic syndrome and atherothrombosis. Circulation 2003; 107: 398-404.
34. Fusman G., Mardi T., Justo D. et al. Red blood cell adhesiveness/ aggregation, C-reactive protein, fibrinogen, and erythrocyte sedimentation rate in healthy adults and in those with atherosclerotic risk factors. Am. J. Cardiol. 2002; 90: 561-563.
35. LeRoy E. C., Black C. M., Fleischmajer R. et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J. Rheumatol. 1988; 15: 202-205.
36. Atkinson J. P. C-reactive protein: A rheumatologist's friend revisited. Arthr. and Rheum. 2001; 44 (5): 995-996.
37. Otterness I. G. The value of C-reactive protein measurement in rheumatoid arthritis. Semin. Arthr. Rheum. 1994; 24: 91-104.
38. Blann A. D., Illingworth K., Jayson M. I. Mechanisms of endothelial cell damage in systemic sclerosis and Raynaud's phenomenon. J. Rheumatol. 1993; 20 (8): 1325-1330.
39. Smith E. A., Kahaleh M. B., LeRoy E. C. The acute phase response in scleroderma. Differing responses to intravenous PGE1. Clin. Exp. Rheumatol. 1986; 4 (4): 341-345.
40. Ribbens C., Martiny Porras M., Franchimont N. et al. Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment. Ann. Rheum. Dis. 2002; 61 (2): 161-166.
41. La Montagna G., Meli R., Criscuolo T. et al. Bioactivity of prolactin in systemic sclerosis. Clin. Exp. Rheumatol. 2004; 22 (2): 145-150.
42. Frediani B., Baldi F., Falsetti P. et al. Clinical determinants of bone mass and bone ultrasonometry in patients with systemic sclerosis. Clin. Exp. Rheumatol. 2004; 22 (3): 313-318.
43. La Montagna G., D'Angelo S., Valentini G. Cross-sectional evaluation of YKL-40 serum concentrations in patients with systemic sclerosis. Relationship with clinical and serological aspects of disease. J. Rheumatol. 2003; 30 (10): 2147-2151.
44. Komura K., Sato S., Hasegawa M. et al. Elevated circulating CD40L concentrations in patients with systemic sclerosis. J. Rheumatol. 2004; 31 (3): 514-519.
45. Jinnin M., Ihn H., Yamane K. et al. Clinical features of patients with systemic sclerosis accompanied by rheumatoid arthritis. Clin. Exp. Rheumatol. 2003; 21 (1): 91-94.
46. Mimura Y., Ihn H., Jinnin M. et al. Rheumatoid factor isotypes and anti-agalactosyl IgG antibodies in systemic sclerosis. Br. J. Dermatol. 2004; 151 (4): 803-808.
47. Allanore Y., Borderie D., Lemarechal H. et al. Correlation of serum collagen I carboxyterminal telopeptide concentrations with cutaneous and pulmonary involvement in systemic sclerosis. J. Rheumatol. 2003; 30 (1): 68-73.
48. Akesson A., Scheja A., Lundin A., Wollheim F. A. Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide. Arthr. and Rheum. 1994; 37 (5): 729-735.
49. Hasegawa M., Sato S., Fujimoto M. et al. Serum levels of interleukin 6 (IL-6), oncostatin M, soluble IL-6 receptor, and soluble gp130 in patients with systemic sclerosis. J. Rheumatol. 1998; 25 (2): 308-313.
50. Blann A. D., Sheeran T. P., Emery P. von Willebrand factor: increased levels are related to poor prognosis in systemic sclerosis and not to tissue autoantibodies. Br. J. Biomed. Sci. 1997; 54 (1): 5-9.